Just as email effectively killed the Acalabrutinib hand-stamped letter, the mobile device has changed the way we do everything from reading books to watching sports. What will this new era hold? Some analysts see longer acting products that will alter and confront accepted methods of treatment; a potential redistribution

of the existing products because of lower prices of recombinants, driven by companies having to look for new markets, with a related potential for surplus; and new players who will challenge the incumbents as they bring gene-transfer therapies and treatments to trial and begin to market them [2]. Innovation in the pharmaceutical industry will forever change the landscape in which it operates. And Erlotinib cost our community

will feel the impact of that change in all its aspects. At the WFH, we are here to serve all who have bleeding disorders and we welcome all treatment products as long as they are safe and prove useful to those individuals and countries in need. And this movement in the industry seems rather positive as it indicates we may have greater quantities and variety of products with which to treat those in need. Against this backdrop of changing faces and products, we will also see a shift from an economic perspective. Developing markets – the BRICS countries (Brazil, Russia, India, China and South Africa) as well as Mexico, Turkey and Ukraine – will account for one-third of the world’s GDP by 2020 – just 6 years away [3]. Twenty years beyond that, if infrastructure, regulatory environments and distribution systems evolve and improve, developing markets will have caught up with more mature markets. While disruption will be cause for much reflection on – and re-definition of – business models, for people affected by a bleeding disorder,

it heralds a time of celebration for a number of reasons [2]: Factor replacement therapy usage per patient will increase in developing markets; The improved convenience of longer acting therapies in the pipeline could begin to encourage more 上海皓元医药股份有限公司 people, particularly adults, to consider ongoing prophylaxis therapy; We expect to see acceptance of the real possibility of lower priced recombinant and possibly plasma-derived therapies in emerging markets; We will come closer to achieving treatment for all. These are opportunities we cannot afford to miss. Collectively, we must connect more effectively to technology and not allow ourselves to be complacent. We cannot stop advocating for better treatment, and better access to treatment, regardless of geography, the level of medical knowledge, or the wealth of a nation. The bleeding disorders community has the power, the means, and the potential knowledge to bridge, and eradicate, the divide between the developed and developing worlds we serve.